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A B S T R A C T  ( 1 9 8 )   
Background: The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. 
Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to 
a single dose schedule, beliefs about vaccine dosage in low and middle income countries (LMICs) are poorly 
understood. We investigated acceptability of dose-reduction among girls, and parents/guardians of girls, rand-
omised to receive one, two or three doses in an HPV vaccine dose-reduction and immunobridging study (DoRIS 
trial) in Tanzania. 
Methods: Semi-structured interviews with girls (n = 19), and parents/guardians of girls (n = 18), enrolled in the 
study and completing their vaccine course. 
Results: Most participants said they entrusted decisions about the number of HPV vaccine doses to experts. 
Random allocation to the different dose groups did not feature highly in the decision to participate in the trial. 
Given a hypothetical choice, girls generally said they would prefer fewer doses in order to avoid the pain of 
injections. Parental views were mixed, with most wanting whichever dose was most efficacious. Nonetheless, a 
few parents equated a higher number of doses with greater protection. 
Conclusion: Vaccine trials and programmes will need to employ careful messaging to explain that one dose offers 
sufficient protection against HPV should emerging evidence from ongoing dose-reduction clinical trials support 
this.   
1. Introduction 
Persistent human papillomavirus (HPV) infection, a pre-requisite for 
development of cervical cancer, can be prevented by three highly effi-
cacious licensed vaccines that protect against infection with a number of 
high-risk HPV genotypes [1,10]. The vaccine is usually targeted to girls 
prior to sexual debut and is currently administered in two or three dose 
schedules. As of May 2020, 127 countries across the world had intro-
duced HPV vaccination programmes, but this comprised only 28% 
(22/78) of low-and-middle-income countries (LMIC) compared with 
71% (105/147) of higher income nations [2]. There are stark global 
disparities, such that populations with the highest incidence of HPV 
infection and cervical cancer mortality are least likely to be protected by 
vaccination. By 2014, only 1% of women targeted by immunisation 
programmes globally were from low income countries [4]. 
Worldwide by 2014, 50.1% of the target population (typically girls 
between 9 and 15 years) had received one vaccination but only 39.7% 
had received the full course (minimum of two doses) [4]. Evidence from 
high income countries suggests that non-completion of the allocated 
dosing schedule is linked to ethnicity and healthcare coverage alongside 
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other factors [5]. Number of doses is rarely investigated in studies of 
vaccine acceptability in low-income settings. However, in a small Ken-
yan study of women attending family planning services, more mothers 
said that they would be willing to have their daughters vaccinated with 
HPV vaccine if one injection was required (86%) compared with three 
(31%) [6]. Such preferences appeared underpinned by concerns about 
cost to families, an important barrier to acceptability in Sub-Saharan 
Africa [7]. A review of delivery strategies in LMIC concluded that 
non-vaccination and non-completion were driven more by program-
matic factors, including lack of awareness and school absenteeism, than 
by opposition to the vaccine itself [8]. Specifically, in their review of 
health systems in LMIC, Wigle and colleagues highlighted the challenge 
of reaching girls with three doses of the vaccine where school attendance 
is very low [9]. 
A number of resource-poor countries have been hesitant in scaling- 
up HPV vaccination programmes, citing concerns about the sustain-
ability of offering a multi-dose vaccine schedule to pre-adolescent and 
adolescent girls [10]. Feasibility of vaccine delivery is a key determinant 
of vaccine acceptability at national level [11] and the three-dose 
regimen is a known barrier to successful vaccination [12]. A reduction 
in the number of doses required is considered crucial to efforts to in-
crease coverage in low income settings [4]. A single dose vaccination 
schedule would increase compliance, simplify delivery and allow 
considerable savings in terms of vaccines, consumables, disposal, 
outreach visit costs and staff time away from health facilities [13]. 
There is emerging biological evidence from studies conducted in 
Costa Rica [14] and India [15] that one dose could protect against HPV 
infection. If immune responses, efficacy and safety are confirmed to be 
similar following one dose compared to multi-dose schedules, adoption 
of a single dose regimen is likely to be rapid, particularly in 
resource-poor settings. Although the case for a single dose seems robust 
in terms of cost and accessibility, it cannot be simply assumed that one 
dose will be more acceptable to parents/guardians and their daughters. 
In Sub-Saharan Africa, vaccine uptake has tended to be high even where 
knowledge is low [7], but information is lacking on beliefs about dosage 
and whether these might have a bearing on vaccine acceptability. Prior 
to country programmes administering single-dose HPV vaccination, 
such questions are hypothetical, but they can be explored in more 
concrete ways among participants in current HPV dose-reduction trials. 
We report views on dosage from a qualitative acceptability study 
conducted during the second year of an HPV vaccine trial (A Dose 
Reduction Immunobridging and Safety Study of two HPV vaccines in 
Tanzanian girls (DoRIS; clinicaltrials. gov: NCT02834637)) taking place 
in Mwanza, Tanzania [16]. 
2. Methods 
2.1. Brief introduction to the parent trial 
DoRIS is an unblinded, randomised trial whose main objectives are to 
compare the immunogenicity and safety of one, two and three doses of 
two different HPV vaccines in 9–14 year old Tanzanian girls [16,17]. 
After taking informed consent from parents/guardians and informed 
assent from potential participants, the trial enrolled 930 girls and 
randomly assigned them to one of 6 arms (155 girls per arm). Each arm 
received either the 2-valent (Cervarix®) or 9-valent (Gardasil-9®) vac-
cine, given as either one, two, or three dose schedules. Participants are 
being followed up for up to 60 months following the first dose. Blood is 
taken at specific follow-up visits for immunogenicity measurements, 
malaria testing and for antibodies to herpes simplex type 2 (HSV-2), a 
marker of sexual behaviour. 
This paper presents findings of a nested qualitative acceptability 
study which aimed to understand attitudes of trial participants towards 
vaccine dosage and the HPV vaccine in general. Here we focus on 
objective one of the qualitative study: to explore views on vaccine 
dosage amongst trial participants and their parent/guardians, and 
whether these views have a bearing on acceptability of the vaccine. 
2.2. Acceptability study design 
We conducted semi-structured interviews with: i) girls aged 9 to 14 
(n = 13), (ii) parents of (different) girls (n = 12) and (iii) girls and their 
parent/guardian in paired interviews (6 interviews). Originally the 
study planned to include interviews with individuals who did not 
complete their assigned vaccine schedule but remained in the trial. 
However, no eligible non-completers were identified in the trial (five 
girls (0.5%) missed one or two vaccine doses but left the study (e.g. due 
to relocation or concerns about vaccine safety); two girls (0.2%) missed 
their month 6 visit but were in the single dose arm and so did not miss a 
dose). Data for this qualitative study were collected between January 
and December 2018. 
2.2.1. Sampling 
Girls who had completed their allocated vaccination course and 
attended their clinic visit scheduled for six months after the first vaccine 
dose, were eligible for selection. Girls were stratified by trial arm and 
age (9–11 or 12–14 years), and then selected for inclusion in the qual-
itative study using simple random sampling within strata. Random se-
lection was done by the trial data manager using a computer 
randomisation algorithm. In each arm, 15 participants were selected 
(two back-up participants per interviewee in case of refusal). This list of 
90 girls was then viewed by the research team to check for reasonable 
variation by religion, tribe, rural versus urban location, and primary 
versus secondary school. Parent/guardian interviewees were identified 
via daughters on this list. 
2.2.2. Participant recruitment 
DoRIS trial staff members made initial contact with selected partic-
ipants to introduce the acceptability study and to inform them that a 
member of the acceptability study team would be in touch with them. A 
female qualitative researcher followed up with each girl’s parent/ 
guardian to invite them to a brief introductory meeting to explain the 
study. This was held at a place convenient to participants (usually home; 
sometimes place of work). The researcher explained the study, indicated 
whether a girl, parent or paired interview was being requested, provided 
information sheets and addressed any questions. An interview date and 
place was scheduled a few days later with those expressing willingness 
to participate. If a parent or daughter declined to participate, a 
replacement was selected from the same stratum (this occurred only 
once). Parents provided written informed consent for themselves and on 
behalf of their daughters, depending on interview type. Illiterate parents 
provided witnessed consent by thumb print. Girls provided written 
assent prior to interview. Depending on participants’ preferences, in-
terviews were conducted at their home or at the study clinic. Choice of 
venue was based on convenience and need for privacy and quiet. 
2.2.3. Interview topic guide 
The interviews probed for existing knowledge of the HPV vaccine 
and cancer; experience of getting the HPV vaccine (e.g. pain, side- 
effects; daughter’s experience if parent was interviewed), views on 
vaccine dosage; and how the decision was made to take part in the DoRIS 
trial. The paired interviews explored parent-child dynamics as well as 
individual perspectives. 
To facilitate discussion, participants were also presented with a set of 
cards, each describing a different factor that they may or may not have 
considered in deciding whether to participate in the trial. They were 
asked to sort the cards into three piles which reflected whether they had 
‘thought about this a lot’, ‘thought about this a little or ‘did not consider 
this’. In paired interviews, parents and daughters sorted the cards 
together, with discussion. The cards included the following factors: 
severity of cervical cancer; risk of getting cervical cancer if not vacci-
nated; how effective the vaccine is; own age/daughters age; how safe the 
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vaccine is; side-effects such as pain/fever; the fact that the vaccine 
protects against a disease that is sexually transmitted; and dosage. The 
card exercise was abandoned for younger girls (including some in paired 
interviews) because early interviewees found it too difficult. 
2.2.4. Analysis 
All interviews were audio recorded with permission, transcribed 
verbatim into Swahili and then translated into English. Transcripts were 
checked for clarity and quality before and after translation. Data were 
analysed thematically following the Framework approach (Ritchie & 
Lewis, 2003) [18]. The analysis team (KM, TE and GM) first familiarized 
themselves with the data by reading through the English transcripts. An 
initial thematic coding frame was developed based on the study aims 
and initial reading of data. The coding frame was refined through 
reading of transcripts and discussion between analysts. All transcripts 
were read and coded by TE and GM in QSR NVivo 11 [19] using the final 
coding frame. The process was iterative and involved regular discussion 
between analysts, and going back and forth between data and inter-
pretation. As a reliability check, a third of randomly selected transcripts 
were double coded and, via discussion, consistency across coders was 
deemed reasonable. 
The card exercise served both as a discussion prompt and a means of 
ranking key factors based on how much they were considered in the 
decision to participate in the trial. Given the qualitative nature of the 
sample, these counts were simply intended to support and validate the 
qualitative insights [20]. 
Ethical approval 
The study was approved by the National Health Research Ethics 
Committee (NatHREC) in Tanzania (ref: NIMR/HQ/R.8a/Vol.IX/2682) 
and the Ethics Committee of the London School of Hygiene and Tropical 
Medicine (ref:11,972). 
3. Results 
3.1. Participants 
The qualitative study participants were daughters and/or parents/ 
guardians who had assented/consented to participate in the DoRIS trial 
and had completed their assigned vaccination schedule. 
We conducted individual interviews with 13 girls and 12 (different) 
parents, plus interviews with 6 (different) girls together with their 
parent/guardian... All participants lived in the trial study location of 
Mwanza, a large city on the south-east edge of Lake Victoria. The sample 
was predominantly urban, Christian and educated to primary level 
(Table 1). 
3.2. Extent to which randomisation by dosage was considered in the 
decision to participate in the trial 
All DoRIS trial participants were informed at the trial recruitment 
stage that they would be randomised to receive one, two or three vaccine 
doses. Among the participants in this qualitative study (all of whom had 
ultimately opted to participate in the trial), dosage did not appear to 
feature highly in their decision to participate. 
As part of the interview, older girls (12–14 years), parents/guardians 
and parent/guardian-daughter dyads were asked to sort a set of cards 
listing potential considerations according to whether they thought about 
them a lot, a little or not at all (see methods and Fig. 1) when they were 
deciding whether or not to participate in the trial. Participants tended to 
think most about the consequences of getting cervical cancer, the risk of 
getting the disease if unvaccinated and the effectiveness of the vaccine: 
“Because I heard that when you get cervical cancer, it can lead you to 
death … and when I heard that there is a cancer vaccine […] I decided to 
take part.” (Girl aged 13 years; 1 dose arm). 
Appreciation of the severity of cervical cancer was sometimes based 
on personal experience: 
“because I have come across several cases … like two of them, people who 
suffered from cervical cancer, so when I saw that there is this vaccine and 
it can help … […] I saw it was good for [my daughter] to participate …”... 
(Mother aged 45–50 years; 3 dose arm) 
The next most common considerations were girl’s age, vaccine 
safety, side-effects and the fact that the vaccine protected against an STI. 
It was notable that all the girls said they considered side-effects such as 
pain and fever, but half the parents said they did not consider this. While 
three-quarters of the parents thought a lot about whether their daughter 
was at an appropriate age for vaccination, only a third of girls did so 
(though note that small numbers mean these observations are only 
indicative). 
Other considerations, particularly for parents, involved the cost of 
treating cervical cancer: 
“the first [consideration] was that I am poor. Because of poverty I will not 
be able to treat my child if she gets that disease because it is expensive to 
treat; what can I do? So I accepted [to join the trial].” (Mother aged 
45–50 years; 2 dose arm). 
Similarly, the provision of free medical treatment during the trial 
was a consideration: 
“Even if I get ill, Dad simply calls them (research team) and I get fetched 
(by the researchers)." (Girl aged 12 years; 3 dose arm) 
Table 1 
Key characteristics of interview sample.   
GIRLS (n = 19) PARENTS (n = 18) 
Type of interview   
Individual 13 12 
Paired 6 6 
Age in years, Median (range) 12 (9–16) 44 (28–72) 
Gender   
Male 0 4 
Female 19 14 
Residential setting   
Urban 15 17 
Peri-urban 4 1 
Religion   
Christianity 16 14 
Islam 3 4 
Current school level   
Primary school 12 – 
Secondary school 7 – 
Education Level of parent   
Primary School – 14 
Secondary school – 2 
Vocational training – 1 
University – 1 
Occupation of parenta   
Vendor, salesman/woman – 6 
Farming, agricultural work – 4 
Housewife – 3 
Business man/woman – 3 
Unemployed – 1 
Other – 5 
Number of HPV vaccine doses received Girls Daughters    
3 doses 5 7 
2 doses 7 5 
1 dose 7 6  
a Some parents gave more than one occupation. 
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3.3. Entrusting the dosage question to experts 
Parents tended to frame the ultimate decision to participate in the 
trial as a matter of placing trust in the scientists and researchers. This 
trust in expertise in some ways simplified the decision to participate as it 
positioned key aspects of the trial – including dosage – as outside of their 
concern: 
“ ….about the number of doses, I did not consider that at all … because 
you (researchers) are the ones who know about [that]. I really don’t 
know anything about [it], so I leave that to you guys to decide … If you tell 
me that within a year there is this number of doses, then it’s okay … 
because I was the one who decided to take part […] We did not think at all 
about how many doses she would receive […] If you tell us 3 vaccine 
doses, or 2 or 1, that’s ok.” (Mother aged 45–50 years; 3 dose arm) 
For the same reason, dosage did not appear to be a factor affecting 
the acceptability of the trial. For instance, the parent below was at pains 
to establish their lack of expertise while simultaneously demonstrating 
this lack through their misunderstanding of the vaccine as ‘treatment’: 
“ …. .… I am not the expert and the ones responsible for treating her are 
the experts who have studied this vaccine. So I may demand for her to be 
vaccinated with four doses which in turn may later be harmful yet the two 
doses could be enough to treat, so I cannot explain it in detail because I am 
not an expert “(Mother aged 45–50 years; 2 dose arm) 
This trust in experts with respect to dosage was illustrative of a 
broader trust, and even ‘faith’, in scientific research among those who 
had opted to participate in the trial: 
“My trust is through the seminars we received from the experts … because 
I am not an expert, I just agree with what I am told by them, as I said 
before I am doing this by faith […] they said it is a successful vaccine so I 
also trust it is going to be effective in her life.” (Mother aged 35–40 
years; 1 dose arm) 
There was also a broader trust in government vaccination pro-
grammes, again sometimes borne of personal experience: 
“[ …] when I was growing up, so many people were dying of smallpox and 
a lot of children died due to measles but […] now even measles […] does 
[not] kill a lot of children and I can see that even smallpox has vanished 
… so that was something that was […] motivating me a lot … " (Mother 
aged 50–55 years; 3 dose arm). 
3.4. Trust and mistrust: the context of decision-making 
The trust exhibited by those who had opted to join the trial may have 
reflected the typically polarised context in which the decision was made. 
Those attending the trial sensitisation meetings were sometimes 
required to weigh up information given by the trial implementers 
against opposition and rumours about vaccine trials circulating among 
neighbours and community members. 
“ … people were saying that white people intend to destroy our kids. Many 
parents had this same view; they’d asked the doctors about it but the 
doctors said it wasn’t true and explained further. So some of them 
believed what doctors said but others quit [decided not to join] …. 
“(Father aged 35–40 years; 2 dose arm) 
These rumours were perceived as fear-inducing. They included that 
the vaccine would plant a bacteria in the body, sterilise their children or 
take away their virginity, and that vaccinations were part of a terrorist 
plot. Parents sometimes encountered these views immediately, on the 
walk home from sensitisation meetings: 
“[after the] parents meeting at school, we were returning home in groups 
[…], they (neighbours/friends) asked us where we were coming from. We 
told them that we were called for cervical cancer vaccine meeting. Others 
said, ‘those things are nonsense. You are going to be planted with bacteria 
which will bring you problems in the future’." Mother aged 40–45 years; 
1 dose arm). 
The decision to participate was complex and involved balancing 
benefit against risks that were difficult to assess without expert knowl-
edge and training. Not having this knowledge themselves, community 
members ultimately had to decide whether to trust what they were told 
by the ‘doctors’ (trial implementers or other health professionals), draw 
on their own experience and knowledge, or listen to the beliefs circu-
lating among the community. Participants described how they actively 
sought out advice from people they trusted, including family members 
and health professionals: 
“I went to consult that doctor (a friend). I told her that our children have 
been called at school for this [vaccine trial] and parents had also been 
informed. She told me that is fine, there is no problem ….so I became 
certain after talking to that doctor and I got peace.” (Mother aged 40–45 
years; 1 dose arm). 
The sensitisation meetings and work by the trial team to explain the 
trial were fundamental in the decision: 
“ … but when they came and educated us and gave us the forms, we read 
and understood that this vaccine is very important and that is how I was 
courageous enough to let my daughter take part in the vaccination” 
(Mother aged 50–55 years; 2 dose arm) 
The parent above perceived the decision as one requiring courage. 
Fear of vaccination among community members and hesitancy about 
taking part, is illustrated in this account of parents changing their mind 
Fig. 1. Card exercise showing extent to which factors were considered in decision to participate in trial.  
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about participation after seeing that girls who were vaccinated were 
fine: 
“ … so later when they (parents who had previously refused to join the 
trial) saw that my daughter was doing well, they decided to […] ask […] 
me. I informed them that there were no more chances left.” (Mother aged 
45–50 years; 3 dose arm) 
Against this backdrop of fear and hesitancy and having ultimately 
opted to put their faith in the scientists, the trust displayed by those 
taking part appeared to extend to all aspects of the trial, including the 
decisions around dose. 
3.5. Hypothetical preferences for one, two or three doses 
Both parents and daughters were asked whether, given a choice, they 
would prefer one, two or three doses of the vaccine. Some (particularly 
the girls) found this hypothetical question difficult; they were able to 
state a preference but not always able to give a reason. Some found it 
difficult to think of advantages of one dose schedule over another. 
Others, particularly parents, were reluctant to give an opinion, believing 
that it was a matter of scientific research. A few girls were confused 
between dosage and trial randomisation arm, assuming that arm A must 
be the ‘best’ since A is associated with a top grade at school. Several 
parents misunderstood or forgot the randomisation by dosage, believing 
allocation to be about child age, weight or degree of sexual risk. Among 
those who did express views on dosage, four considerations emerged: 
avoidance of pain, societal benefit, cost saving, and efficacy. 
Pain avoidance. Almost all of the girls said they would prefer one dose 
of the vaccine, rather than two or three. This was primarily due to fear of 
the injection and a desire to avoid the pain it caused: 
‘I love the vaccination but I am afraid […] I feel like the syringe is too long 
and I can’t imagine that all of it enters my body’ (Girl aged 10 years; 2 
dose arm). 
Most girls expressing a preference to avoid pain did so on the un-
derstanding that one dose was just as likely to be efficacious as two or 
three. However, for some girls fear of the injection over-rode any con-
cerns about which number of doses was most effective; they would 
prefer one dose regardless. Girls in the one dose arms reported feeling 
‘lucky’ and happy with their group since they had received fewer in-
jections than girls in other arms. A few girls who had received three 
doses reported negative reactions from those receiving one or two doses, 
although this did not deter them from participation: 
“From the whole group, I was the only one who was given 3 doses, they 
(other students) asked me, ‘you mean they are injecting you three times?! 
… We are being injected only once. It is better if you just quit’[…] I just 
ignored them”, (Girl aged 14 years (paired interview); 3 dose arm). 
Societal benefit: Four parents expressed a preference for one dose on 
the basis that one dose per child would mean the vaccine could be 
distributed among far more children for the same cost: 
“Well, I would wish that my daughter would have been given one vaccine 
dose so that others also benefit. It will spread among people […] It means 
that for that girl who had received two vaccine doses, then two children 
would have been vaccinated” (Mother aged 50–55 years; 3 dose arm). 
Reduced cost: A few parents also raised the point that outside of the 
trial context, one dose would imply less personal cost. In addition to 
payment for the vaccine itself, they mentioned the cost of travelling to a 
clinic and potential lost earnings involved in accompanying children. 
Asked why they thought the scientists might be investigating whether 
one dose could be effective, one parent thought it could be about 
broader cost savings: 
“Perhaps, they (researchers) have seen that one vaccine dose has the 
same protection and that is why they see a possibility of reducing [it]. 
They [the trial scientists] mentioned that these vaccine doses are very 
expensive, so probably to also reduce cost”. (Mother aged 35–40 years; 
1 dose arm). 
Conversely, in the context of the vaccine trial, three doses were seen 
as beneficial by some, because they implied more clinical attention to 
their daughter and this was viewed as a benefit: 
“I really wished [my daughter] had received three vaccine doses. […] 
Yes, there is an extra thing (in three doses) because they have researched 
on her more. (Mother aged 45–50 years; 2 dose arm). 
Efficacy: Most parents recalled that the trial sought to establish 
whether different numbers of doses might be equally efficacious. As 
described above, the majority felt efficacy was ultimately a matter for 
the scientists, and none of the participants expressed a strong preference 
for a particular dose based on efficacy. A few parents and girls thought 
that two or three doses might offer more protection and would be more 
‘helpful’ (compared with one dose). There was also a perception that 
two or three doses would stay in the body longer, offering a longer 
period of protection. One parent thought that three doses were each a 
third as ‘strong’ as one dose, and another expressed concern therefore 
that one dose might be ‘too much medicine’ in one go (mother age 50–55 
years; 3 dose arm). 
One parent whose daughter received two doses said she wished ‘that 
if there is a possibility of adding some more, then give her that remaining one 
so that she can finish’ (Father aged 45–50 years; 2 dose arm), implying a 
belief that a girl receiving less than three doses had not received the full 
course. Belief that three doses offered more protection was also implied 
in the view that if a girl is sexually active, she may require more doses: 
“Because I see [HPV] is a result of sex. It means if she likes [sex] so much, 
it’s better to receive two vaccines” (Mother aged 40–45 years; 1 dose 
arm). 
Of girls expressing an opinion on efficacy, several thought that the 
doses were equivalent: 
“that one dose is as powerful as the other doses”. (Girl aged 14 years: 1 
dose). 
Only a few girls said they thought that two/three doses might be 
more efficacious than one dose. These girls tended to view two and three 
doses as equally effective and generally said that they would prefer two 
doses because it implied one less injection. 
4. Discussion 
This study explored whether dosage mattered to girls, and parents/ 
guardians of girls, who had enrolled in an HPV vaccine dose reduction 
trial and completed all of their scheduled doses. We found that being 
randomly allocated to the number of doses did not feature highly in their 
decision to participate. Instead participants thought primarily about the 
consequences of getting cervical cancer, the risk of getting it if unvac-
cinated and the effectiveness of the vaccine. Girls were particularly 
concerned about the pain of injection. In the context of the trial, de-
cisions about dosage were viewed as outside of participant expertise and 
therefore not their concern. Entrusting this to experts reflected, to some 
extent, the polarised context in which the decision to participate in the 
trial was enacted. Having ultimately opted to put their faith in the sci-
entists, the trust displayed by those taking part appeared to extend to all 
aspects of the trial, including randomisation by dose. Given a hypo-
thetical choice, girls generally said that they would prefer fewer doses in 
order to avoid the pain of injections. Views among parents were mixed, 
with most wanting whichever dose was most efficacious. Nonetheless, a 
few parents equated a higher number of doses with greater protection, 
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believing that the vaccine would stay longer in the body or that three 
injections implied the full course. In the context of a trial, three doses 
was also perceived as implying more medical attention to an enrolled 
daughter. 
This study is rare in its explicit focus on dosage in relation to HPV 
vaccine acceptability and in directly seeking the views of girls as well as 
their parents. It contributes to a sparse literature on actual HPV vaccine 
acceptability in low-income settings. The main limitation is that the 
sample comprises only girls, and/or parents/guardians of girls, who 
agreed to participation in a vaccine trial and who completed their clinic 
visit scheduled for six months after the first vaccine dose. Although we 
originally planned to interview girls, and parents of girls, who did not 
complete their vaccine course, no girls met the study protocol criteria for 
non-completion of the vaccine schedule (i.e. missing one or more vac-
cine doses) but remaining in the study. Five girls (0.5%) missed one or 
two vaccine doses but left the study (e.g. due to relocation); two girls 
(0.2%) missed their month 6 visit but were in the single dose arm and so 
did not miss a dose. The absence of non-completion in itself provides 
further support for the qualitative evidence suggesting that dosage 
randomisation did not have a bearing on the acceptability of the trial 
among those opting to enrol in it. However, we do not know whether 
other families or girls declined participation because of concerns related 
to vaccine dosage. The active community liaison system for the trial had 
not detected any negative rumours related to vaccine dosage at the 
completion of the acceptability study, but it is possible that we missed 
rumours circulating among the wider community. It is also worth noting 
that the DoRIS trial did not have a placebo control arm and this may 
have led to enrolment of a group more positively disposed to the HPV 
vaccine (since getting the vaccine was certain). Some of the positivity 
towards the HPV vaccine may have reflected an element of resoluteness 
in the context of perceived opposition from neighbours. Compared with 
the rumours around vaccine safety, uncertainty around dosage may have 
appeared a risk of much lower magnitude. It is difficult to determine 
whether, outside of a trial context, dosage would remain of small 
significance. 
In terms of the qualitative design, we opted to include paired in-
terviews because we were interested in whether the dynamic between 
parent/guardian and child could provide insight into decision making 
processes. What we actually found was that daughter participants ten-
ded to say less and defer to their parent/guardian, such that these in-
terviews were less good at drawing out daughter views. Finally, in 
common with all qualitative research, the study provides a nuanced 
account of the range of views and experiences, but cannot comment on 
their frequency or associations with other factors of interest. 
The girls and parents interviewed in this study often struggled with 
the concept of randomisation by dosage. Difficulty understanding the 
concept of randomisation has also been identified among adolescents 
(16–19 years) in the context of HIV vaccine trials in high-income 
country settings [21,22]. Communicating risk is complicated [23]; key 
questions regard the right level of information, how to couch uncer-
tainty and the risk of introducing doubt or legitimising rumours by 
attempting to counter them. In the context of African vaccine trials, it is 
suggested that limited knowledge can elevate concerns among partici-
pants [24–27]. However, retention in the DoRIS trial has been very high 
with >95% attending their clinic visit scheduled for 24 months after the 
first vaccine dose. This suggests that participants do value their ongoing 
participation in the trial. 
We found a tendency among a few parents/guardians to equate a 
higher number of doses with greater protection. Any national vaccina-
tion programme switching to a lower dose will need to consider how to 
address this belief. Since fewer doses are also recognised to be cheaper, 
there may also be suspicion that a switch to fewer doses is driven by a 
desire (by government or vaccinators) to cut costs. These views may be 
counterbalanced by the greater convenience (and in some cases cost- 
saving) to participants of a single dose, and for girls, the benefit of 
fewer injections. Any education strategies designed to manage a switch 
to a lower dose regimen could incorporate these findings into their 
messaging. Vaccination programmes over many decades have shown 
that strategies beyond information-giving are also required to support 
and facilitate implicit trust in the science of vaccination [28]. Strategies 
such as community engagement are essential but cannot necessarily 
prevent opposition and there is tension between recruiting sufficient 
numbers for trials and empowering communities to potentially say ‘no’ 
to participation [29]. 
5. Conclusions 
A switch to a single-dose vaccine will alleviate some but not all of the 
barriers to vaccine coverage. In settings where the vaccine is adminis-
tered in primary care, it will remove the need for additional visits [30] 
and the risk that subsequent doses will be forgotten [31]. It will also 
significantly reduce overall delivery costs and may make it easier to 
integrate a single vaccination visit with other school-based health in-
terventions. Our study of HPV trial participants suggests that switching 
to a single-dose vaccine would not pose major acceptability issues 
among those pre-disposed to vaccine uptake. Given the mis-
understandings highlighted in our study, vaccine trials and programmes 
will need to employ careful messaging to highlight the benefits of a 
single dose and to explain that one dose offers sufficient protection 
against HPV. 
In addition, other system-level barriers common to many resource- 
poor settings - inadequate infrastructure, limited heath professional 
training, lack of means to pay, lack of a regular health care provider, 
inconsistent endorsement of vaccine by health care providers, little 
contact with medical system; low school attendance [32,33] - will still 
need to be tackled and efforts to address them maintained. Since 
completion of this study, global vaccination efforts to combat the spread 
of Cov-Sars-2 have drawn renewed attention to vaccine hesitancy and 
barriers to implementation of programmes, and will undoubtedly have a 
bearing on how these challenges are tackled in future. 
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